The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China

Abstract Background PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may differ in different types of advanced solid tumours. Methods PD-L1 expressio...

Full description

Bibliographic Details
Main Authors: Yanhui Chen, Yating Wang, Hongli Luo, Xue Meng, Wei Zhu, Di Wang, Hui Zeng, Henghui Zhang
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Experimental Hematology & Oncology
Subjects:
TMB
Online Access:http://link.springer.com/article/10.1186/s40164-020-00173-3
id doaj-301929f987174ea1a6ce877b5bc03101
record_format Article
spelling doaj-301929f987174ea1a6ce877b5bc031012020-11-25T03:07:54ZengBMCExperimental Hematology & Oncology2162-36192020-08-019111310.1186/s40164-020-00173-3The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in ChinaYanhui Chen0Yating Wang1Hongli Luo2Xue Meng3Wei Zhu4Di Wang5Hui Zeng6Henghui Zhang7Institute of Infectious Diseases, Beijing Ditan Hospital, Key Laboratory of Emerging Infectious Diseases, Capital Medical UniversityGenecast Biotechnology Co., Ltd.Genecast Biotechnology Co., Ltd.Genecast Biotechnology Co., Ltd.Genecast Biotechnology Co., Ltd.Genecast Biotechnology Co., Ltd.Institute of Infectious Diseases, Beijing Ditan Hospital, Key Laboratory of Emerging Infectious Diseases, Capital Medical UniversityInstitute of Infectious Diseases, Beijing Ditan Hospital, Key Laboratory of Emerging Infectious Diseases, Capital Medical UniversityAbstract Background PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may differ in different types of advanced solid tumours. Methods PD-L1 expression, TMB, and PD-1+ Tils (tumour-infiltrating lymphocytes) infiltration and their relationships were assessed in 6668 advanced solid tumour specimens across 25 tumour types. CD8+ T cell infiltration was analysed in 347 NSCLC samples. The associations of these biomarkers with the therapeutic effect of PD-1 inhibitor were analysed in a cohort of NSCLC samples. Results PD-L1 expression levels and TMB in different tumour types varied widely and their relationship was not significantly correlated in most cancer types, with only a small association across all specimens (Spearman R = 0.059). PD-1+ Tils infiltration was positively correlated with PD-L1 expression across all samples (Spearman R = 0.3056). However, there is no such correlation between PD-1+ Tils infiltration and TMB. In NSCLC samples, CD8+ T cell infiltration was correlated with PD-1+ Tils infiltration and PD-L1 expression but not with TMB (Spearman R = 0.4117, 0.2045, and 0.0007, respectively). Patients in the CR/PR group (anti-PD-1 therapy) had higher levels of PD-L1 expression, TMB, PD-1+ Tils, and CD8+ T cell infiltration, and many patients in this group exhibited concomitantly elevated levels of multiple biomarkers. Conclusions Our results showed the PD-L1 expression status and TMB in various types of advanced solid tumours in Chinese patients and their relationships with PD-1+ Tils and CD8+ T cell infiltration, which may inform ICI treatment.http://link.springer.com/article/10.1186/s40164-020-00173-3PD-L1TMBPD-1Solid tumourImmunotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Yanhui Chen
Yating Wang
Hongli Luo
Xue Meng
Wei Zhu
Di Wang
Hui Zeng
Henghui Zhang
spellingShingle Yanhui Chen
Yating Wang
Hongli Luo
Xue Meng
Wei Zhu
Di Wang
Hui Zeng
Henghui Zhang
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
Experimental Hematology & Oncology
PD-L1
TMB
PD-1
Solid tumour
Immunotherapy
author_facet Yanhui Chen
Yating Wang
Hongli Luo
Xue Meng
Wei Zhu
Di Wang
Hui Zeng
Henghui Zhang
author_sort Yanhui Chen
title The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
title_short The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
title_full The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
title_fullStr The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
title_full_unstemmed The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
title_sort frequency and inter-relationship of pd-l1 expression and tumour mutational burden across multiple types of advanced solid tumours in china
publisher BMC
series Experimental Hematology & Oncology
issn 2162-3619
publishDate 2020-08-01
description Abstract Background PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may differ in different types of advanced solid tumours. Methods PD-L1 expression, TMB, and PD-1+ Tils (tumour-infiltrating lymphocytes) infiltration and their relationships were assessed in 6668 advanced solid tumour specimens across 25 tumour types. CD8+ T cell infiltration was analysed in 347 NSCLC samples. The associations of these biomarkers with the therapeutic effect of PD-1 inhibitor were analysed in a cohort of NSCLC samples. Results PD-L1 expression levels and TMB in different tumour types varied widely and their relationship was not significantly correlated in most cancer types, with only a small association across all specimens (Spearman R = 0.059). PD-1+ Tils infiltration was positively correlated with PD-L1 expression across all samples (Spearman R = 0.3056). However, there is no such correlation between PD-1+ Tils infiltration and TMB. In NSCLC samples, CD8+ T cell infiltration was correlated with PD-1+ Tils infiltration and PD-L1 expression but not with TMB (Spearman R = 0.4117, 0.2045, and 0.0007, respectively). Patients in the CR/PR group (anti-PD-1 therapy) had higher levels of PD-L1 expression, TMB, PD-1+ Tils, and CD8+ T cell infiltration, and many patients in this group exhibited concomitantly elevated levels of multiple biomarkers. Conclusions Our results showed the PD-L1 expression status and TMB in various types of advanced solid tumours in Chinese patients and their relationships with PD-1+ Tils and CD8+ T cell infiltration, which may inform ICI treatment.
topic PD-L1
TMB
PD-1
Solid tumour
Immunotherapy
url http://link.springer.com/article/10.1186/s40164-020-00173-3
work_keys_str_mv AT yanhuichen thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT yatingwang thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT hongliluo thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT xuemeng thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT weizhu thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT diwang thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT huizeng thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT henghuizhang thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT yanhuichen frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT yatingwang frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT hongliluo frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT xuemeng frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT weizhu frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT diwang frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT huizeng frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
AT henghuizhang frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina
_version_ 1724668558276820992